Clinical Trials for Orion

Explore 19 clinical trials worldwide

Showing 1-19 of 19 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: Orion

Clinical Trials (19)

NCT07148128
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
PHASE1/PHASE2Recruiting
110 participants
Started: Jul 28, 2025 · Completed: Jan 31, 2028
5 conditions2 sponsors3 locations
NCT06607939
ORB-021 In Patients With Advanced Solid Tumors
PHASE1Recruiting
36 participants
Started: Nov 21, 2024 · Completed: Feb 28, 2027
1 condition1 sponsor2 locations
NCT06370351
A Phase I/II Clinical Trial with SENS-501 in Children Suffering from Severe to Profound Hearing Loss Due to Otoferlin (OTOF) Mutations
PHASE1/PHASE2Recruiting
12 participants
Started: Jun 21, 2024 · Completed: Jul 31, 2031
8 conditions1 sponsor2 locations
NCT06354010
Cross-sectional and Prospective Study to Characterize Early-onset Presbycusis
N/ARecruiting
100 participants
Started: Jun 14, 2024 · Completed: Jul 31, 2027
1 condition1 sponsor2 locations
NCT06353386
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
PHASE1/PHASE2Recruiting
220 participants
Started: May 20, 2024 · Completed: Mar 31, 2028
1 condition2 sponsors77 locations
NCT06136598
A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)
PHASE1Active, not recruiting
14 participants
Started: Jan 30, 2024 · Completed: Mar 14, 2027
2 conditions2 sponsors3 locations
NCT06280157
A Follow up Study of Group B Streptococcus (GBS)-NN/NN2 Vaccine in Healthy Volunteers
N/AEnrolling by invitation
55 participants
Started: Jan 18, 2024 · Completed: Jan 31, 2028
1 condition2 sponsors1 location
NCT06136624
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
PHASE3Recruiting
1,310 participants
Started: Dec 31, 2023 · Completed: Aug 2, 2028
1 condition2 sponsors279 locations
NCT06136650
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
PHASE3Active, not recruiting
1,314 participants
Started: Dec 18, 2023 · Completed: Dec 2, 2030
2 conditions2 sponsors319 locations
NCT06104449
A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)
PHASE1Active, not recruiting
6 participants
Started: Nov 14, 2023 · Completed: Apr 12, 2026
2 conditions2 sponsors3 locations
NCT06725758
Two-part, First-in-Human Study on ODM-212 in Subjects with Selected Advanced Solid Tumours
PHASE1/PHASE2Recruiting
315 participants
Started: Oct 26, 2023 · Completed: Dec 31, 2027
1 condition1 sponsor1 location
NCT05664191
Levosimendan as Treatment of Aneurysmal SubArachnoid Haemorrhage
PHASE2Recruiting
30 participants
Started: Oct 13, 2023 · Completed: Apr 13, 2026
1 condition2 sponsors1 location
NCT05947474
ORB-011 In Patients With Advanced Solid Tumors
PHASE1Active, not recruiting
55 participants
Started: Aug 21, 2023 · Completed: Dec 31, 2025
1 condition1 sponsor2 locations
NCT05402813
Natural History in Children Up to 16 Years with Mild to Profound Hearing Loss Due to Mutations in GJB2 / OTOF Genes
N/ARecruiting
180 participants
Started: Nov 18, 2022 · Completed: Nov 18, 2028
7 conditions1 sponsor1 location
NCT05570058
Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis
PHASE2Active, not recruiting
48 participants
Started: Sep 8, 2022 · Completed: Jan 9, 2025
2 conditions2 sponsors31 locations
NCT05486182
Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer
PHASE4Active, not recruiting
153 participants
Started: Feb 8, 2022 · Completed: Jan 31, 2026
1 condition3 sponsors11 locations
NCT04736199
Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer
PHASE3Active, not recruiting
669 participants
Started: Feb 23, 2021 · Completed: Jan 30, 2026
1 condition2 sponsors131 locations
NCT04832607
Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections
PHASE3Recruiting
149 participants
Started: Aug 27, 2019 · Completed: Sep 30, 2028
4 conditions10 sponsors33 locations
NCT03436485
Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer
PHASE1/PHASE2Active, not recruiting
204 participants
Started: Mar 19, 2018 · Completed: Jul 31, 2026
1 condition1 sponsor20 locations